Cryoport
31 named things its latest annual report says its results depend on, each in the company's own words. 12 of them are also named by other companies we've read.
Customers
Unnamed largest customer (Life Sciences Services)
earns from · 10.2% of our total revenueDuring the year ended December 31, 2025, one customer in our Life Sciences Services reportable segment accounted for 10.2% of our total revenue.Business (Item 1)
Also named by ENPH
Moffitt Cancer Center
earns fromStrategic collaboration with Moffitt Cancer Center, Tampa, Florida; awarded exclusive BioStorage services rightsBusiness (Item 1)
Suppliers
Partners and platforms
DHL Supply Chain International Holding B.V. (DHL)
$133.0 millionDuring the second quarter of fiscal year 2025, we completed the divestiture of our specialty courier CRYOPDP business to designated affiliates of DHL Supply Chain International Holding B.V. (“DHL”) for $133.0 million.Business (Item 1)
Third-party shipment and carrier services
depends onnamed as a riskWe rely on our distribution system including third-party shipment and carrier services to transport our shippers containing biological material.Risk factors (Item 1A)
Other companies
2026 Convertible Senior Notes
$176.6 millionnamed as a riskAs of December 31, 2025, the estimated fair value of the 2026 Convertible Senior Notes was $176.6 million.Market risk (Item 7A)
The Blackstone Group Inc.
250,000 sharesnamed as a riskIn connection with financing our acquisition of MVE Biological Solutions, on October 1, 2020, we completed the sale of 250,000 shares of a newly designated Series C Convertible Preferred Stock, par value $0.001 (“Series C Preferred Stock”), at a price of $1,000 per share, the original purchase price, to funds affiliated with The Blackstone Group Inc., or Blackstone.Risk factors (Item 1A)
MVE reporting unit goodwill impairment
$54.6 millionnamed as a riskFor example, for the year ended December 31, 2024, we recorded non-cash impairment charges of $54.6 million related to the full impairment of the goodwill associated with our MVE reporting unit and $9.2 million related to the impairment of certain trademarks and tradenames.Risk factors (Item 1A)
Cell and gene therapy market
earns from · $33.4 millionIncreased revenue from the support of commercial cell and gene therapies by $7.4 million, or 28.6%, to $33.4 million, supporting 20 commercial cell and gene therapies as of December 31, 2025Business (Item 1)
Competitors
World Courier (Cencora)
competes withLife Sciences Services competition is primarily with specialty couriers, who fall into the category of coopetition and include companies such as World Courier (a Cencora company), UPS Healthcare, Quick (a Kuehne+Nagel company), and Biocair.Business (Item 1)
UPS Healthcare
competes withLife Sciences Services competition is primarily with specialty couriers, who fall into the category of coopetition and include companies such as World Courier (a Cencora company), UPS Healthcare, Quick (a Kuehne+Nagel company), and Biocair.Business (Item 1)
Azenta Life Sciences
competes withLife Sciences Products competition is with companies offering cryogenic systems products such as Azenta Life Sciences, Phase 2, and IC Biomedical.Business (Item 1)
American Red Cross
competes withCompetition for our cryopreservation services in particular includes companies such as the American Red Cross and Gift of Life Biologics.Business (Item 1)
Places
Americas
earns from · 74.5Our geographical revenue, by origin, for the years ended December 31, 2025, 2024 and 2023, were as follows:Business (Item 1)
Also named by BLK, DELL, EMR, FDS, FICO, GGG, GS, HLIO and 6 more
Chengdu, China
operates innamed as a riskDuring the course of the COVID-19 pandemic, certain of our facilities experienced disruptions, such as our MVE Biological Solutions manufacturing facility in Chengdu, China that was temporarily impacted by COVID-19 lockdowns in China during the third quarter of 2022, and similar disruptions could occur in the future.Risk factors (Item 1A)
Also named by MPWR
Liège, Belgium
operates inIntroduced in late 2024, the platform currently operates from two purpose-built facilities located in Houston, Texas, and Liège, Belgium, to support global clinical and commercial cell therapy programs.Business (Item 1)
Commodities and inputs
Euro
exposed to its price · 18% of our consolidated revenuesnamed as a riskFor example, for the year ended December 31, 2025, revenue from our international business, which accounted for 18% of our consolidated revenues, increased by $0.9 million in comparison with the same period in the prior year as a result of fluctuations in foreign exchange rates.Market risk (Item 7A)
Also named by ABBV, ABNB, ABT, ADBE, ADI, AME, AMG, AMGN and 186 more
Chinese Yuan
exposed to its pricenamed as a riskNet sales and related expenses generated from our international business are primarily denominated in the functional currencies of the corresponding subsidiaries and primarily include Euros, British Pounds, and Chinese Yuan.Market risk (Item 7A)
Also named by ABT, ASO, BEN, CHRW, CROX, DORM, ESI, EXPD and 13 more
Regulators
U.S. Food and Drug Administration (FDA)
subject tonamed as a riskCertain of our operations are subject to regulation by the FDA or similar foreign regulatory agencies.Risk factors (Item 1A)
Also named by A, ABBV, ABT, AMGN, ARE, ARWR, ATR, AXGN and 112 more
Federal Aviation Administration (FAA)
subject tonamed as a riskAdditionally, our data logger may be subject to regulation and certification by the FDA, the FCC, and the FAA.Risk factors (Item 1A)
Also named by ACHR, AIR, ALK, AMT, AVAV, BA, BRK/B, CCI and 27 more
China National Medical Products Administration
subject tonamed as a riskFor example, we are aware that China’s National Medical Products Administration has had discussions that may require certain of our products to be registered as Class II medical devices.Risk factors (Item 1A)
Laws and programs
General Data Protection Regulation (GDPR)
subject to · up to 4 percent of total company revenuenamed as a riskThe GDPR established new requirements regarding the handling of personal data and includes significant penalties for non-compliance (including possible fines of up to 4 percent of total company revenue).Risk factors (Item 1A)
Also named by A, AB, ABNB, ADBE, ADP, AGX, AIOT, AJG and 100 more
U.S. tariffs (Trump administration trade policy)
subject tonamed as a riskFor example, beginning in 2025, the current Trump administration instituted changes in trade policies that included the imposition of higher tariffs on imports into the U.S. and other government regulations affecting trade between the U.S. and other countries where we conduct our business, such as China and the European Union (EU), among others.Risk factors (Item 1A)
Also named by A, AAPL, ACHR, ADI, AEHR, AEP, AIOT, AKAM and 170 more
IATA Dangerous Goods Regulations
subject tonamed as a riskFor example, shipments using our solutions may be required to comply with the shipping requirements promulgated by the CDC, the Occupational Safety and Health Organization (“OSHA”), the DOT as well as rules established by the IATA and the ICAO.Risk factors (Item 1A)
21 CFR Parts 210 & 211 (cGMP)
subject toStorage of biological materials that are classified as drug products for human therapeutic use (either for investigational use or commercially approved) or materials used in the manufacture of drug products for human therapeutic use, is regulated by the FDA under Title 21 Code of Federal Regulations (“CFR”) part 210 & 211.Business (Item 1)
21 CFR Part 820
subject toMVE is compliant with current GMP regulations which are enforced by the FDA through registration and audit of compliance with 21 CFR Part 820 and GMP.Business (Item 1)
ICAO Technical Instructions
subject toOur Cryoport Express® and ELITE™ Shippers meet Packing Instructions 602 and 650 and are certified for the shipment of Class 6.2 Dangerous Goods per the requirements of the ICAO Technical Instructions for the Safe Transport of Dangerous Goods by Air and IATA.Business (Item 1)
EU Medical Device Directive (MDD)
subject toOur MVE Biological Solutions cryogenic stainless-steel freezers and aluminum dewars are certified to the Medical Device Directive (MDD) in the EU.Business (Item 1)
ISO 21973:2020
subject toAll our operations are also certified to ISO 9001:2015 for quality management systems, ISO 13485:2016 for medical devices, where applicable, and ISO 21973:2020 for the transportation of cells for therapeutic use.Business (Item 1)
FDA REMS elimination for CAR-T therapies
In June 2025, the FDA eliminated Risk Evaluation and Mitigation Strategy (“REMS”) requirements for approved BCMA- and CD19-directed autologous CAR-T therapies, which is a change expected to reduce administrative and logistical barriers, thereby expanding patient access.Business (Item 1)
Technology
Cryoportal software platform
depends onnamed as a riskWe rely upon certain critical information systems, including our Cryoportal® software platform which is used by our customers and business partners to automate the entry of orders, prepare customs documentation and facilitate status and location monitoring of shipped orders while in transit.Risk factors (Item 1A)